Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Share-based Compensation (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Share-based Compensation for 4 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 9.73% to $3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.3 million through Dec 2025, up 1.49% year-over-year, with the annual reading at $13.3 million for FY2025, 1.49% up from the prior year.
  • Share-based Compensation hit $3.5 million in Q4 2025 for Taysha Gene Therapies, up from $3.3 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $5.3 million in Q1 2022 to a low of $1.7 million in Q1 2023.
  • Historically, Share-based Compensation has averaged $3.3 million across 4 years, with a median of $3.3 million in 2025.
  • Biggest five-year swings in Share-based Compensation: crashed 68.57% in 2023 and later soared 90.93% in 2024.
  • Year by year, Share-based Compensation stood at $4.1 million in 2022, then tumbled by 52.04% to $2.0 million in 2023, then surged by 63.41% to $3.2 million in 2024, then grew by 9.73% to $3.5 million in 2025.
  • Business Quant data shows Share-based Compensation for TSHA at $3.5 million in Q4 2025, $3.3 million in Q3 2025, and $3.2 million in Q2 2025.